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Abstract: Hepatitis B virus (HBV) infection is a serious problem and earlier studies in Papua New
Guinea have reported a high prevalence of hepatitis B virus infection. These studies were undertaken
using insensitive tests and before an expanded immunization program. The current HBV status is
therefore uncertain. A retrospective study to investigate the HBV status was carried out using blood
donor data at Nonga General Hospital, East New Britain Province, Papua New Guinea, from January
2003 to December 2018. Additional data for Human Immunodeficiency Virus, syphilis and hepatitis
C virus were also collected. Data were analysed using NCSS statistical software. The mean hepatitis
B antigen (HBsAg) sero-prevalence was 21% for the period of study and showed a downward trend
over the period of the study, which may reflect the effect of the extended immunization program.
HBsAg prevalence in male donors (23%) was significantly higher than females (16%). Donors living
in Pomio district had a significantly lower proportion of sero-positive HBsAg donors (7%) than
Gazelle (22%), Kokopo (22%) and Rabaul (20%), which was attributed to this district’s geographical
isolation. Ethnically, Pomios donors (8%) had significantly lower HBsAg prevalence than the Taulils,
(29%), Bainings (21%) and Tolais (21%). Fifteen to nineteen year olds (23%) were the predominant age
group affected, and vertical or perinatal transmission was probably the primary transmission route.
Our findings call for greater awareness on the part of public policy makers and should be considered
when planning future public health campaigns.
Keywords: Hepatitis B; human immunodeficiency virus; Syphilis; Hepatitis C; Co-infections; blood
donors; Papua New Guinea
1. Introduction
Hepatitis B (HBV) infection is a serious problem both globally and nationally. Earlier studies in
certain areas of Papua New Guinea (PNG) reported a high prevalence of Hepatitis B virus infection,
especially in the highlands of PNG [1–3], the Sepik province [4] and in the Autonomous Island of
Bougainville [5]. These studies were undertaken in the general population using insensitive tests and
before an expanded immunization program. The HBsAg prevalence among blood donors in Papua
New Guinea was reported in Port Moresby Blood transfusion services as 22.7% [6], and in the whole
country in 1996 as 15% [7]. In about the same period, 24% of blood donors were reported positive for the
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HBsAg in Bougainville [8]. A study undertaken in 1998 that reviewed the HBsAg sero-positivity status
in blood donors of Pacific countries stated the prevalence of HBV in PNG was 16.7%, second highest to
the Solomon Islands (19.5%) [9]. Despite the high prevalence of HBV antibodies found in populations
in Papua New Guinea [1–9], a study in 1987 looking at the aetiology of jaundice in a medical ward of
one of the Hospitals in PNG failed to detect viral hepatitis in any of the clinical cases with jaundice [6].
This is in contrast to an earlier study published in 1976, which had examined 17 clinical cases, eight of
which were strongly suggestive of viral hepatitis clinically [10]. Since the introduction of neonatal
hepatitis B Immunoglobulin (hep B Birth Dose) immunization in 1989 and subsequent addition of
the national three-dose infant hepatitis B (hep B3) vaccination program in 1992 [11], little work to
establish the prevalence of HBV has been conducted in blood donors in Papua New Guinea. A recent
comparative retrospective study in blood donors in Port Moresby General Hospital found a hepatitis B
antigen (HBsAg) prevalence of 22.9% in blood donors in 2016 [12]. Co-infections were also indicated in
the latter study at 7.3% (20/275) and were mostly seen in Family replacement donors. Co-infections
were mainly with Human Immunodeficiency Virus (HIV) and syphilis [12], owing to shared means of
transmission [13].
East New Britain province (ENBP) is one of the five island provinces of PNG that lies between four
and six degrees south of the equator (Figure 1). It has a total population of 327,355 people with a high
literacy rate (86.6%) among the four island provinces and second in the country to the National Capital
District (92.4%) [14]. It is also known as the fastest growing province in the country economically [15].
It has four districts inhabited by four distinct ethnic groups, namely the Tolais, Pomios, Taulils and the
Bainings, which are all Melanesians (Figure 1). The Kokopo and the Rabaul districts are semi-urban
areas and are inhabited predominantly by the Tolais, the Gazelle district is inhabited by the Tolais,
the Taulils and the Bainings, while the Pomio district is inhabited predominantly by the Pomios.
The current HBV status in ENBP is uncertain, and therefore this study was undertaken to establish the
prevalence of HBV and related co-infections in blood donors to help with policy making in the province.
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Figure 1. Map of East New Britain Province, Papua New Guinea; Map drawn by and with permission
from; Ashley Lais (2020). Lands Department, East New Britain Province, Papua New Guinea.
2. Materials and Methods
A retrospective observational cross-sectional study to investigate the HBV, HIV, hepatitis C virus
(HCV) and Syphilis status of blood donors and related epidemiological risk factors in ENBP was carried
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out using blood donor data at Nonga General Hospital (NGH), ENBP, PNG from January 2003 to
December 2018. Mandatory pre-screening for health and social status are done on all prospective blood
donors presenting for donation at the blood Transfusion Service. This is in concordance with the PNG
National Health Department Blood Policy, in partnership with the World Health Organization [16].
Epidemiological variables included in the data analysis were age, gender, district of origin,
ethnicity, infection status and diagnostic tests. Ethnicity was based on the village that was recorded in
the database for that patients place of residence, with the assumption that people from a particular
village would all be of the same ethnicity, since tribal clustering is still relevant to PNG. Infectious
status was determined in the hospital as part of their diagnostic service using commercially available
kits and relevant demographic data were recorded at the time. The following kits were used by
the hospital for diagnostic purposes (note that this study only looked at the results of the tests
and the authors were not involved in the diagnostic process). The Gelatin Particle Agglutination
assay using Serodia ®-HBs PA (specificity 100%; sensitivity 99.0%. Fujiebio Inc., Tokyo, Japan) was
used to detect HBsAg before 2010. This test had a reported minimum detection limit of 0.5 ng/mL
HBsAg. After 2010, immunochromatographic assays were used for HBsAg detection, which included
DetermineTM HBsAg (sensitivity 100%; specificity >98%. Abbott Laboratories, Dainabot Co. Ltd.,
Tokyo, Japan). Alternatively, the Hepa S-Ag test kit using reverse passive hemagglutination (specificity
100%; sensitivity 99%. Green Cross Medical Science, Yongin, South Korea) or the Chembio Diagnostic
Systems kit (specificity 100.0%; sensitivity 99.0%. Medford USA) was used, depending on availability.
Test kits used were in keeping with World Health Organization (WHO) recommended assay required
for EIAs (sensitivity 100%; specificity ≥98%) and RDTs (sensitivity ≥99%; specificity ≥98%) [17].
WHO recommended limit of detection for both EIAs and RDTs is ≤0.13 IU/mL.
The HIV antibody rapid screening kit, Determine™ HIV-1/2 (specificity 99.87%; sensitivity 100%,
Abbott Laboratory, IL, USA) was used together with the Immuno Comb® II HIV 1 and 2 kit (specificity
99.4%; sensitivity 100%. Bispot kit PBS Organics and Israel 2005,) to screen for HIV. This was followed
in series by the SERODIA®-HIV-1/2 test kit for HIV, which is an in vitro diagnostic test kit for the
detection of antibodies to HIV type1 and/or type 2 (HIV-1/HIV-2) in human serum/plasma (specificity
100%; sensitivity 100%. Fujirebio Inc., Japan).
Two tests were used for the screening of Syphilis; the Syphilis TPHA liquid Hemagglutination
test for qualitative and quantitative detection of T. pallidum antibodies in serum specimens (sensitivity
98.5%; specificity 100%. Hexagon, Germany) or the Syphilis RPR Rapid test for qualitative and
semi–quantitative detection of antibodies, associated with syphilis, in serum or plasma (specificity
and sensitivity not given by manufacturer. HUMAN Gesellschaft für Biochemica und Diagnostica
mbH Max-Planck-Ring 21 65205 Wiesbaden, Germany). In addition, the SD BIOLINE Syphilis 3.0 test
was used to test for Syphilis, which is a solid-phase immunochromatographic assay for the qualitative
detection of antibodies of all isotypes (IgG, IgM, IgA) against Treponema pallidum (TP) (sensitivity
99.3%; specificity 99.5%. Standard Diagnostic, Korea,). The SD BIOLINE HCV (02FK10, 02FK16,
02FK17) chromatographic testing kit was used to test for the HCV in 2018 blood donors (sensitivity
100%; specificity 100%. SD Standard Diagnostics, Inc., Korea,). This test was introduced to all blood
bank centres in PNG in 2018, and therefore only HCV test results for 2018 are reported for our study.
Other tests used for the diagnosis of active hep B and C infections were not performed in this setting
because of financial constraints. Positive donors for HBsAg were excluded from repeat donation,
however, donors were not always informed of their results unless they came back for their results or
came back for a second donation. Additionally, all tests positive for HBsAg were not repeated.
Apparent prevalence (AP) and its corresponding 95% confidence interval (CI) were calculated
using proportions of donors at NGH, testing positive on one or more of the diagnostic tests described
above. The Chi-Square test was used to look for significant associations between the proportion of
HBsAg seropositive donors and demographic variables. The level of significance was set at p ≤ 0.05%.
Odds Ratios were calculated to determine the strength of association between the proportion of
seropositive HBsAg donors and demographic variables.
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For the multivariable logistic regression models, survey data were entered into Microsoft Excel
(2007) and the computer software program NCSS (NCSS Inc., Kaysville, UT, USA) for analysis.
The associations between seropositive HBsAg donors and various risk factors were analysed using
Chi-square tests (i.e., univariate analysis). Risk factors with a p-value < 0.20 on univariate analysis were
selected to be included in the multivariable logistic regression models [18]. A hierarchical stepwise
forward elimination process with switching of variables based on log likelihood values was used
to determine the best fitting logistic regression model. NCSS has a built-in algorithm that does the
selection process and several iterations were run before the final model was selected, which contained
the best fitting log likelihood value and only the variables with a p-value < 0.05 on the Wald test [19,20].
Due to collinearity between the District and Ethnic groups, two separate models were run with the
inclusion of only one of these variables in each model.
Ethical Clearance was granted by the Nonga General Hospital Management on 6 February 2017
and the University of Papua New Guinea School of Medicine & Health Sciences Research Ethics
Committee (UPNG SMHS REC) approved the research on 10 October 2016. All records collected were
de-identified and only data required for analysing trends was collected.
3. Results
A total of 24,478 donor records from 2003–2018 were analysed. Of these, 41.4% (n = 10,128) were
excluded because of missing variables of interest. Of the remaining 58.6% (n = 14350), 67.5% (n = 9686)
were males and the rest were females (32.5%, n = 4664). The average number of donors per year and
standard deviation over the period studied was 897 ± 497 and ranged from 129 in 2017 to 1832 in 2003
(Appendix A).
The mean ages and standard deviations for males and females were 31 ± 11.6 and 31.8 ± 11.3 years,
respectively. Though there was no statistical difference observed between the mean age of males and
females, the age range was 74 and 58 years, respectively. In both genders, 20-year olds donated more
frequently than the other ages. More males continued to donate annually throughout the study period.
The prevalence of sero-positive HBsAg donors with a single infection for the period of the
study (2003–2018) was found to be 19% (95% CI 18.9–20.2%). Trends showed a decline from 35%
(95% CI 33.0–37.4) in 2003 to 0.4% (95% CI −0.1–0.9) in 2014 before rising again in 2015 and 2016.
Single infections with syphilis and HIV showed increasing trends to 2011. After a decline in 2012,
syphilis infections increased in 2013 and 2014, and remained constant in the next 3 years, and declined
in 2018 (Figure 2, Appendix A, Table A1). Because of common modes of transmission, an increase in
positive cases of HIV and Syphilis infection in 2015 and 2016 may have also impacted on the increase
in HBsAg prevalence during the same time period. The prevalence of double and triple infections was
found to be 2% (95% CI 2.0–2.2%). The prevalence of sero-positive HBsAg donors with a double or
triple infection increased from 0.6% (95% CI 0.23–0.99%) in 2007 to 15.8% (95% CI 13.3–18.2) in 2011
before declining in 2012 from 1.6% (95% CI 0.5–2.7%) to 0% in 2014, then rising again in 2016 (Figure 3).
The annual distribution of HBsAg infections for each age group shows declining hep B virus
infection with increasing years (Figure 4, Appendix A Table A2). In 2003, the HBsAg prevalence in
15–29-year age group was 36% (95% CI 33–38) and declined to 9% (95% CI 5–12) in 2009. An increase
was again observed in 2010 (27%; 95% CI 22–32); which again declined to 1% (95% CI −0.3–2) in 2014.
In 2015, a rise in prevalence was again observed (17%; 95%CI 10–24); which continued to increase
in 2016 (25%; 95% CI 19–31) then started to decline again in 2017 (25%, 95% CI 11–32) and 8% (95%
CI 5–19) in 2018. The same pattern was observed in other age groups. This may have reflected the
introduction and fluctuating trends in the neonatal hep B Immunoglobulin immunization coverage in
PNG [20].
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Figure 2. The trend of single infection by hepatitis B virus (HBV), human immunodeficiency virus (HIV),
Syphilis and hepatitis C virus (HCV) from 2003–2018, based on calculated estimated prevalence rates.
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Figure 3. Comparison of trends of HBV single and co-infection prevalence rates in blood donors
from 2003–2018.
The prevalence in sero-positive HBsAg first time donors (23%; 95% CI 21.6–23.4) was significantly
higher than repeat donors (16%; 95% CI 14.8–16.6 (Table 1). This appears to be linked to the large
number of male donors as when stratified by gender, the proportion of HBsAg sero-positive first-time
male donors (29; 95% CI 27.7–30.2) was higher than repe t male (12; 95 CI 10.6–12 5) do ors, yet
the proportion of HBsAg positive repeat female donors (26; 95% CI 24.3–28.4) were) was higher than
first time female donors (11; 95% CI 9.7–12.0) (T ble 2, Figure ). The significantly higher HBsAg
seroprevalence observed in first time donors could be due to the fact that repeat donors positive for the
hep B virus are almost always exempted from donation.
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Table 1. Mean prevale ce rates of HBV infections by age groups, donor frequency, districts, ethnicity an
co-infections in East N w Britain province between 2003–2018.
Demographic Proportion Positive Prevalence %(95% CI) x
2 p-Value
Total HBsAg Infection 3102/14350 21 (21.0–22.0)
Singl infection 2804/14350 19 (19.0–19.8)
Age group
15–29 1669/7272 23 (22.5–23.4)
30–44 843/4809 17 (17.0–18.1) 130.41 <0.001
45–59 270/2100 13 (12.0–13.6)
≥60 22/169 6 (4.6–8.4)
Donor frequency
Repeat donor 986/6269 16 (14.8–16.6) 102.89 <0.001
First time donor 1818/8081 23 (21.6–23.4)
District
Kokopo 622/2826 22 (21.2–22.8)
Gazelle 1775/7904 22 (22.0–22.9) 27.38 <0.001
Pomio 11/152 7 (5.2–9.3)
Rabaul 694/3468 20 (19.3–20.7)
Ethnicity
Bainings 99/360 21 (19.7–23.5)
Pomios 13/142 8 (6.2–10.6) 19.51 <0.001
Taulils 30/73 29 (24.7–33.5)
Tolais 2960/10673 21 (21.0–22.1)
Co & Triple infection
HBsAg/SYPHILIS 120 0.8 (0.6–1.0)
HBsAg/HIV 101 0.7 (0.5–0.9) 38.21 <0.001
HBsAg/HCV 65 0.5 (0.3–0.6)
Triple Infection 12 0.1 (0.0–0.2)
Total 298/14350 2 (2.0–2.2)
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Table 2. Mean prevalence rates of HBsAg by gender for single and co-infections among districts, ethnic
groups and age groups in East New Britain province between 2003–2018.
Males Females
Demographic Proportion Prevalence % Proportion Prevalence % X2 p-Value
Positive 95 CI% Positive 95% CI
Gender 2236/9686 23 (22.6–23.5) 866/4664 18 (18.0–19.1) 39.91 <0.001
Single HBsAg Infection 2023/9686 21 (20.5–21.3) 781/4664 16 (16.0–17.3)
Donor Frequency
Repeat Donors 517/4487 12 (10.6–12.5) 469/1782 26 (24.3–28.4) 714.58 <0.001
First Time Donors 1506/5199 29 (27.7–30.2) 312/2882 11 (9.7–12.0)
District
Kokopo 428/1924 22 (21.3–23.2) 194/902 21 (20.1–22.9)
Gazelle 1270/5255 24 (23.6–24.8) 505/2649 19 (18.3–19.8)
Pomio 8/101 8 (5.3–10.6) 3/51 5 (2.7–9.1) 45.99 <0.001
Rabaul 530/2406 22 (21.2–22.9) 164/1062 15 (14.4–16.5)
Ethnicity
Bainings 70/294 23 (21.4–26.3) 29/165 17 (14.7–20.5)
Pomios 9/103 8 (6.0–11.5) 4/52 7 (4.1–11.3) 26.11 0.002
Taulils 26/73 35 (30.1–41.1) 4/30 13 (7.2–19.4)
Tolais 2131/9216 23 (22.7–23.6) 829/4417 18 (18.0–19.4)
Age Group
15–29 1306/5120 25 (24.9–26.1) 483/2152 22 (21.6–23.3)
30–44 663/3054 21 (21–22.4) 281/1755 16 (15.2–16.9) 183.98 <0.001
45–59 236/1366 17(16.3–18.3) 99/734 13 (12.3–14.7)
≥60 31/146 21 (17.9–24.6) 23-Mar 13 (6.1–19.9)
Double and Triple HBsAg Infections
HBsAg/Syphilis 100 1.0 (0.8–1.2) 20 0.4 (0.2–0.6))
HBsAg/HIV 67 0.7 (0.5–0.9) 34 1.0 (0.5–1.0)
HBsAg/HCV 36 0.4 (0.3–0.5) 29 0.6 (0.4–0.9)) 149.1 <0.001
Triple Infection 10 0.1 (0.0–0.2) 2 0.0 (0.0–0.1)
Total 213/9686 2 (2.0–2.4) 85/4664 2 (1.6–2.0)
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Figure 5. Proportion of HBsAg positive first time and repeat blood donors between 2003–2018.
i est proportion of sero-positive HBsAg d nors was aged 15–29 years (23 , 95% CI
2.5–23.4). Donors livi g in P mio d s rict h d a significantly lower proportion of sero-positive
(7 ; 95% CI 5.2–9.3) than Gazelle (22%; 95% CI 22.0–22.9), Kokopo (22%; 95% CI 21.2–22.8) and
Rabaul (20%; 95 CI 15.3–20.7). Ethnically, the Pomio people had a signific ntly lower proporti n of
sero-positive HBsAg donors (8%; 95 CI 6.2–10.6) than the Bainings, Taulis and Tolais (Table 1) but thi
could be related to district, as ethnicity tended to be clus ered according to th distri t they lived in.
Co-infections of sero-positiv HBsAg don rs wi h syphilis were more common than co-infections with
HIV, HCV and triple infections (Table 1). When stratified by gender, the proportion of sero-positive
HBsAg male donors (21%; 95% CI 20.5–21.3) was significantly higher than female donors (16%; 95% CI
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16.0–17.3), with the highest prevalence in the Taulils males (35%; CI 30.1–41.1) (Table 2). The prevalence
of sero-positive HBsAg donors was lowest in both Pomios men and women (Table 2).
Two logistic regression models were done to identify risk factors in the districts and among ethnic
groups since district and ethnic groups showed collinearity. Model one (Table 3), which includes
district, uses Gazelle, which has the highest prevalence of HBsAg, as a reference and shows that Rabaul
(OR = 0.78) and Pomio (OR = 0.27) both had lower odds of having donors positive to HBsAg than
Gazelle. No difference in HBsAg prevalence could be shown between Kokopo and Gazelle districts.
In this model, there is no significant association between HBsAg-positive donors and those positive
for HCV or HBsAg (p = 0.06). There was a strong association between HBsAg positive donors and
donors positive for HIV (OR = 4.7). Age groups 30–44 years (OR = 0.8) and 45–59 years (OR = 0.6)
were less likely to be HBsAg positive than the 15–29-year age group. There was no difference in risk
between 15–29 and ≥60 years old, but this may be due to the small number of ≥60-year-olds in the
survey. Males were more likely to be HBsAg positive than females (OR = 1.3). The final model 1
was therefore: HBsAg = 1 = 0.00 − 0.03*(DISTRICT = “KOKOPO”) − 1.30*(DISTRICT = “POMIO”) −
0.25*(DISTRICT = “RABAUL”) + 1.55*(HIV = 1) − 0.23*(Age_2 = 2) −0.59*(Age_2 = 3) − 0.33*(Age_2 =
4) + 0.27*(Gender = “M”). The model was found to correctly classify HIV seropositive donors 51.7% of
the time.
Table 3. Multivariable logistic regression model 1 (excluding ethnicity) for risk factors associated with
HBsAg positive blood donors in east New Britain province (ENBP), 2003–2018.
Independent Variable Regression Coefficient SE Wald Z-Value Wald p-Value Odds Ratio Lower 95% CI Upper 95% CI
B0: Intercept 0.00 0.04 −0.02 0.99 0.99 0.92 1.08
DISTRICT = “KOKOPO” −0.03 0.05 −0.50 0.62 0.97 0.88 1.08
DISTRICT = “POMIO” −1.30 0.32 −4.10 <0.01 0.27 0.15 0.51
DISTRICT = “RABAUL” −0.25 0.05 −4.736 <0.01 0.78 0.70 0.86
HIV = 1 1.55 0.13 12.353 <0.01 4.71 3.68 6.02
Age = 15–29 years vs.
30–34 years −0.23 0.05 −4.873 <0.01 0.80 0.73 0.87
Age = 15–29 years vs.
25–59 years −0.59 0.07 −8.770 <0.01 0.55 0.48 0.63
Age = 15–29 years vs.
≥60 years −0.33 0.20 −1.683 0.09 0.72 0.49 1.06
Gender = ”M” 0.27 0.05 5.866 <0.01 1.31 1.19 1.43
Model 2 (Table 4) that includes ethnicity shows that previous donors are less likely to be HBsAg
positive (OR = 0.8). Pomio donors are less likely to be HBsAg positive than the Bainings (OR = 0.57)
and no difference in risk can be shown between the Taulils and the Bainings or between Tolais and
Bainings. Unlike, Model 1, donors positive for HCV were shown in this model to have less chance of
being HBsAg positive (OR = 0.39), which means district was probably confounding this relationship.
HCV exposure may therefore be associated with ethnicity. Male donors were confirmed to be more at
risk of having HBsAg sero-positivity than females (OR1.3). The model confirmed that old donors were
less likely to be HBsAg positive (OR = 0.84) than new donors. The final model 2 was, therefore, HBsAg
= 1 = −0.02 + 0.29*(Gender = “M”) + 1.58*(HIV = 1) − 0.18*(OLD_NEW = “OLD”) − 0.21*(Age_2 =
2) − 0.57*(Age_2 = 3) − 0.28*(Age_2 = 4) − 0.56*(ETHNICITY = “POMIO”) + 0.21*(ETHNICITY =
“TAULIL”) + 0.00*(ETHNICITY = “TOLAI”) − 0.94*(HCV = 1). The model was found to correctly
classify HIV seropositive donors 55.6% of the time.
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Table 4. Multivariable logistic regression model 2 (excluding district) for risk factors associated with
HBsAg positive blood donors in ENBP, 2003–2018.
Independent Variable RegressionCoefficient Standard Error Wald Z-Value Wald Prob Level Odds Ratio Lower 95% C Upper 95% C
B0: Intercept −0.02 0.12 −0.12 0.90 0.99 0.78 1.25
Gender = “M” 0.29 0.05 6.27 <0.01 1.33 1.22 1.45
HIV = 1 1.58 0.13 12.57 <0.01 4.84 3.79 6.19
OLD_NEW = “OLD” −0.18 0.04 −4.16 <0.01 0.84 0.77 0.91
Age = 15–29 years vs.
30–34 years −0.21 0.05 −4.59 <0.01 0.81 0.74 0.89
Age = 15–29 years vs.
25–59 years −0.57 0.07 −8.33 <0.01 0.57 0.50 0.65
Age = 15–29 years vs.
≥60 years −0.28 0.20 −1.41 0.16 0.76 0.51 1.11
ETHNICITY = “POMIO” −0.56 0.27 −2.03 0.04 0.57 0.33 0.98
ETHNICITY = “TAULIL” 0.21 0.25 0.86 0.39 1.24 0.76 2.01
ETHNICITY = “TOLAI” 0.00 0.12 0.03 0.98 1.00 0.80 1.26
HCV = 1 −0.94 0.48 −1.97 0.05 0.39 0.15 0.99
4. Discussion
The mean calculated HBsAg prevalence in this study is 23% (95% CI 23.0–24.0) and is similar to other
studies found in the region before an expanded programme for immunization was introduced [5,21–24];
regional prevalence’s varied from 17.9% in Fiji [22], 32% in British Solomon Islands [21] and Kiribati [23],
42% in Tahiti [5] and 88% in Tonga [24].
Our study demonstrated a downward trend in HBsAg sero-prevalence from 2003–2018 (Figure 2,
Table 1). This is in accordance with studies done in the Solomon Islands, which demonstrated a decline
in HBsAg prevalence from 32% in 1977 [21] to 25.1% in 1999 [25] to 21.5% in 2007 [26]. Similarly,
Fiji has seen a decline in prevalence from 17.9% in 1982 [22] to 0% in children, 5.6% in adolescents and
3.2% in adults in 2009 [27]. The decline in donor HBsAg prevalence seen in our study, from a high of
35% in 2003 to 5% in 2018 in ENB province, can probably be attributed to the expanded program for
immunization in the province and increased awareness of the disease within communities as a result
of these campaigns. The fluctuating decline in donor HBsAg prevalence infections may have been
indirectly affected by fluctuating hepatitis B immunization coverage rates, which varied from 42%
in 2001 to 61% in 2002, 68% in 2003 and a decline to 61% in 2004. In 2005, coverage increased again
to 67% and 75% in 2006. In 2007 and 2008, a decline in coverage was again recorded from 66–65%,
respectively [28]. Furthermore, the estimation of hep B Birth dose (hep BB) and hep B3 (triple dose)
immunization coverage rates in PNG showed declining rates from 26% in 2009 to 25% in 2018, and 66%
in 2009 to 61% in 2018, respectively [29].
4.1. HBV Infection among the Districts and Ethnic Groups of This Study
The Gazelle, Kokopo and Rabaul districts had the highest prevalences of HBsAg at 22%, 22%,
and 20% respectively, which were twice the Pomio district (Table 1). The Rabaul and the Kokopo
districts are both semi-urban areas, while the Pomio and Gazelle districts are mostly rural. Though both
the Pomio and the Gazelle districts are rural settings, HBsAg seropositivity in the Pomio district
was lower than the Gazelle district (Table 2). In fact, Pomio district has lower odds (OR = 0.3) of
having HBsAg infection than Gazelle (Table 3). A possible factor that may explain this difference
in HBsAg prevalence between Gazelle and Pomio districts could, therefore, be the difference in the
ethnicity of donors in the two areas, with most donors in Gazelle being predominantly Tolais and
Bainings and some Taulils, while the Pomio district is populated almost exclusively by Pomios. In other
studies [30–32], familial clustering is a common risk factor among rural inhabitants, or intra-familial
transmission [33].
Inhabitants of the two semi-urban districts of Rabaul and Kokopo are either located within the
vicinity of a hospital or have easy access to a hospital and blood donation services due to good road
networks, unlike most areas of the Gazelle and Pomio districts. It is not clear from our results, however,
if this had an influence on exposure rates. Although both Rabaul and Kokopo districts are semi-urban,
Rabaul has slightly lower odds of having donors positive for HBsAg than Gazelle, but no difference in
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risk could be shown between Kokopo and Gazelle. The people in Rabaul and Kokopo districts are
predominantly Tolais as is the majority of Gazelle, which could explain the relatively small difference in
prevalence of HBsAg between these districts rather than socioeconomic factors. The fact that Bainings
were clustered together with Taulils and Tolais in Gazelle and were not living in other districts could
explain why no difference in HBsAg prevalence could be shown between these ethnic groups. It is
difficult to explain variations between these ethnic groups, but it could mean that accessibility to basic
health services is not a key factor. Alternatively, isolation of the Pomios, who are mostly accessible
only via air and water transport, may have mitigated against spread to this population. Lifestyle was
seen to be a factor in two rural populations of New Caledonia [34], yet a study in Fiji showed high
prevalence that appeared not to have been affected by location and lifestyle [21]. A study in Tonga
showed increased new cases of HBV infections in rural dwellers compared to urban and attributed this
to a lifestyle in rural settings that predisposed them to increased infection [35]. While this may hold
true for the Taulils, Bainings and Tolais of the Gazelle district, it is in contrast to the Pomios in this
current study, who live mostly in rural areas and yet have the lowest HBsAg prevalence.
The reason why HBV is so prevalent in Tolais is complex but one reason could be that when the
Tolais migrated from nearby New Island Province (NIP) to settle in ENBP, they could have carried
the virus along with them and introduced it to those who were already there. There is a possibility,
therefore, that genetic predisposition could be playing a role amongst the ethnic groups in this study
as well.
The overall literacy rate in the province is high [14] and, in other studies, high literacy rates have
been found to be associated with decreasing HBV infection among rural populations [36,37]. This is
in contrast to this study where the Pomio district has a lower literacy rate as compared to the rest
of the districts in the province and yet has the lowest HBsAg prevalence and odds of being HBsAg
positive, while the Gazelle district has a high literacy rate [38] and yet has a significantly higher HBsAg
prevalence than Pomio.
The logistic regression models generated in this study only had a correct classification rate of 51 to
57%, indicating that numerous other risk factors not included in the models were likely playing a role.
Other factors, such as poor knowledge and attitude about HBV infection, the importance of vaccination
against it, parents being older, and families with low monthly income have all been identified as having
an association with higher HBV prevalence rates [37,39,40].
4.2. HBV Infection among Each Gender and Sub-Age Groups
The disease is more prevalent in males than in females in our study (Table 2). Males are also more
likely to be positive for HBsAg than females (OR = 1.3). This is in contrast to Nkrumak et al. [41],
whose study demonstrated higher HBsAg prevalence in females than males (21.4%, 95%CI 11.6–34.4
vs. 13.2%, 95%CI 10.8–15.9). More males than females were presenting for blood donation in this study,
which is consistent with other similar studies [42,43], and this may be confounding the prevalence of
HBsAg in males. However, the higher prevalence of positive males could also be due to increased male
susceptibility to infection [21] and a gender tendency to chronicity [4]. In this study, HBsAg infection
is lower in the Pomio district among both genders. One possible reason that Pomios males have less
infection could be due to male circumcision practiced in this ethnic group. This practice reduces the
risk of transmission sexually transmitted diseases, as seen in another study [42]. A reason why females
are less at risk, as given by Mazzur and Jones [21], is that females do not venture out of the home to
socialize as often as males.
HBV exposure was seen in our results to be highest among adolescents and young adults in
both genders (Table 1). This is similar to a study done in Bougainville [5] but in contrast to an earlier
long-term study in the Sepik district, where HBV infections increased with age in all populations
studied [3]. Though both Hawkes et al. and Wong et al. [4,5] also employed other markers of past
infections such as the anti-HBc, which increased their detection rates, the general scenario was that,
for both genders, evidence of HBV infection increased with age, although the positivity rate of increase
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varied. This indicated vertical and horizontal acquisition from an early age [21,34,43–46]. In this study,
high levels of HBsAg were seen among teenagers and young adults, the 15–29-year-olds. The highest
prevalence of HBV infection was observed in 2003 among 15–29-year-olds. This may be because donors
aged 16–29 years during this time would not have been vaccinated against the virus, as the vaccine
was first introduced into the country in 1989. This suggests that acquisition was mostly vertical or
perinatal. This is further supported by the fact that IV drug use is rare in these communities.
It could not be concluded in this study if the HBsAg positive donors were chronic carriers as
repeat donors positive for HBsAg were not followed up.
4.3. HBV Co- and Triple Infection with Syphilis, HIV and HCV
According to the World Health Organization [47], about 2.7 million (1%) or 7.4% of people with
HBV are HBV/HIV-co-infected. Our study found that only 0.7% of HBV positive donors co-infected
with HIV. However, donors infected with HIV were more likely to be positive for HBsAg (OR = 4.8),
no significant association between donors positive for HCV and HBsAg was seen. This means that
donors positive for HCV are less likely to be infected with HBV (OR = 0.39).
Many studies have demonstrated continuous occurrence of HBsAg co-infections with HIV apart
from syphilis, especially among asymptomatic MSM [48–56], sex workers [49,50], high-risk sexual
behaviour individuals [48,54] and among the immuno-compromised population [54–57]. Furthermore,
it has been found that the risk of developing HBV chronicity is 5–6 times higher in individuals positive
for HIV than in those negative for it [52]. HIV infection has also been indicated to be increasing in
ENBP [58] and in the country as a whole at an exponential rate [59] and is most common among
the young adults of 20–29 years of age [60]. In our study and others [21,43], this is also the sub-age
group in which HBsAg is significantly prevalent, which is a cause for concern. Although HBV/HIV
co-infection seems to be relatively low in this study as compared to others [61,62], it is imperative
for blood banks in PNG to take note that escape mutants in donors can escape being detected using
conventional assays, posing a greater risk to recipients.
The prevalence of HBsAg/Syphilis and HBsAg/HIV co-infections in this study was significantly
higher than with HCV and triple infections. More males were co-infected with syphilis than females,
while females were more commonly co-infected with HIV than with syphilis and HCV. Triple infection
was more common among males than females (Table 2). This is in contrast to Butsashvili et al. [53],
who did not find any association between being positive for HBsAg and having antibodies against
Treponema pallidum among blood donors. Triple infections with HIV and syphilis have also been
observed in other studies in asymptomatic high-risk individuals such as MSM and sex workers and
is attributed to people not knowing if they are infected [54,55]. A lack of knowledge about having
been infected has been found to result in 3.5 times higher risk than those who know their serological
status [63]. The feedback of results to patients is therefore important in combating these sexually
transmitted diseases.
5. Conclusions
Hepatitis B virus was still prevalent in the overall population in ENBP in 2018 despite existing
control measures, which call for greater awareness on the part of public policy makers in the province,
since it is possible that low levels of escape mutants will remain undetectable in blood donor blood and
may pose a threat to the recipients as has been demonstrated in other studies [59,60]. Transmission
of HBV in this study is likely to be perinatal or vertical, as demonstrated by annual high levels of
HBsAg prevalence in young adults (15–29 years) from 2003–2018 and supported by the fluctuating
hep B immunization coverage over the years [28]. Male donors are at a greater risk of being infected
with HBV than females, which may be attributed to lifestyle. The Pomios people living in the Pomio
district had a significantly lower prevalence of HBV than Kokopo, Rabaul and Gazelle districts or the
Tolais, Taulils and Bainings people, which was attributed to their remoteness and isolation from other
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ethnic groups. Co-infections with HIV in females and syphilis in males is of concern and efforts to
make donors aware of their infective state should be a priority at hospitals testing for these diseases.
These findings should be considered when planning public health campaigns and high-risk
groups need to be targeted for intervention and existing control measure reviewed.
6. Limitations
Syphilis testing only started in 2007 and therefore an accurate conclusion on reactive syphilis cases
could not be drawn from this study. Within the period that syphilis was being tested for, some analysis
was not done periodically due to reasons such as a shortage of reagents or inconsistencies on the part
of the laboratory personnel responsible for the analysis. A total of 32 (0.35%) of the total population
studied had an initial reactive test for HIV and had to undergo confirmatory testing but were never
confirmed, and therefore the percentage of positive cases of HIV in blood donors in this study could
have been higher. Risk factors for the possible ethnicity of blood donors were identified based on
the location (villages) in the districts where their blood was drawn during blood collection and
therefore, the likelihood of misidentifying someone as belonging to that ethnic group is possible but
would constitute a small portion of the sample due to clustering of people along tribal lines in PNG.
Another limitation of this study is the inability to trace repeat donors, and therefore it may have been
possible that some donors had donated more than once but were treated as new donors. Additionally,
seroconversions were not identified and therefore the same people may have been counted more
than once.
Although the specificity and sensitivity of assay kits employed were indicated to be at
WHO-approved levels, limits of detection were not indicated, and therefore this could have impacted
on the results obtained over the years. Consistency in the use of a single assay needs to be improved,
and existing criteria for follow-up of donors positive for HBsAg need to be reviewed.
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Appendix A
Table A1. The annual prevalence rates of single infection for HBsAg, HIV, Syphilis and HCV in blood
donors in East New Britain province from 2003–2018.
Year






2003 645/1832 35 (34.11–36.30) 0/1832 0
2004 439/1414 31 (29.84–32.26) 2/1414 0.1 (0–0.3)
2005 200/712 28 (26.44–29.74) 0/712 0
2006 378/1462 26 (24.73–26.98) 1/1462 0.1 (0–0.2)
2007 451/1641 27 (27.00–29.18) 2/1640 0.1 (0–0.3)
2008 145/952 15(14.09–16.38) 0/952 0
2009 68/687 10 (9.33–11.63) 2/685 0.3 (0–0.8)
2010 144/882 16 (17.97–20.58) 27/867 3.1 (2.0–4.3)
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Table A1. Cont.
Year






2011 52/880 6 (20.34–23.07) 154/855 18 (15.4–20.6)
2012 87/820 11 (11.07–13.32) 41/781 5.3 (3.7–6.8)
2013 10/515 2 (1.68–2.98) 4/510 0.8 (0.02–1.6)
2014 2/531 0.4 (0.12–0.64) 4/528 0.8 (0–1.5)
2015 24/242 10 (11.47–15.80) 3/240 1.3 (0–2.7)
2016 78/445 18 (24.90–29.03) 5/442 1.1 (0.2–2.1)
2017 20/129 16 (19.60–26.91) 2/129 1.6 (0–3.7)
2018 60/1206 5 (4.44–5.68) 25/1888 1.3 (0.8–1.8)
Total 2804/14350 19.21–19.87 272/14237 1.9 (1.7–2.1)
Year Syphilis Single Infection HCV Single Infection
2003 0/1832 Not done 0/1832 0
2004 0/1414 Not done 0/1414 0
2005 0/712 Not done 0/712 0
2006 0/1462 Not done 0/1462 0
2007 20/1633 1.2 (0.7–1.8) 0/1641 0
2008 5/947 0.5 (0.1–1.0) 0/952 0
2009 16/674 2.4 (1.2–3.5) 0/687 0
2010 53/849 6.2 (4.6–7.9) 0/882 0
2011 217/810 26.8 (23.7–29.8) 0/880 0
2012 99/732 13.5 (11.1–16.0) 0/820 0
2013 92/425 21.7 (17.7–25.6) 0/515 0
2014 120/411 29.2 (24.8–33.6) 0/531 0
2015 56/194 28.9 (22.5–35.2) 0/242 0
2016 111/375 29.6 (25.0–34.2) 0/445 0
2017 31/107 29 (20.4–37.6) 0/129 0
2018 133/1037 12.8 (10.8–14.9) 37/1169 3.2 (2.58–3.56)
Total 953/13614 7.0 (6.6–7.4) 37/14313 0.3 (0.22–0.30)
Table A2. The annual distribution of single and co-infections of hepatitis B virus categorized by age
groups in East New Britain province from 2003–2018.
Age Group
(Years) 15–29 Prevalence 30–44 Prevalence 45–59 Prevalence ≥60 Prevalence Annual Prevalence
Year 95% CI 95% CI 95% CI 95% CI Total 95% CI
2003 521/1460 36 (33–38) 98/320 31 (26–36) 24/50 48 (34–62) 2/2 100 (100–100) 649/1832 35 (33–38)
2004 284/804 35 (32–39) 125/477 26 (22–30) 28/122 23 (16–30) 2/11 18 (−5–41) 439/1414 31 (28–33)
2005 137/471 29 (25–33) 57/207 28 (22–34) 6′/33 18 (5–31) 0/1 0 (0–0) 200/712 28 (25–31)
2006 157/660 24 (21–27) 169/609 28 (22–34) 49/180 27 (21–34) 3/13 23 (0.2–46) 378/1462 26 (24–28)
2007 247/833 30 (27–33) 159/577 28 (24–31) 41/205 20 (15–26) 12/26 46 (27–65) 459/1641 28 (26–30)
2008 78/405 19 (15–23) 52/392 13 (10–17) 14/145 10 (5–15) 1/10 10 (-9–29) 145/952 15 (13–18)
2009 25/292 9 (5–12) 39/266 15 (10–19) 6/126 5 (1–9) 0/3 0 (0–0) 70/687 10 (8–13)
2010 91/339 27 (22–32) 61/385 16 (12–20) 16/146 11 (6–16) 2/12 17 (−4–38) 170/882 19 (17–22)
2011 58/300 19 (15–24) 63/305 21 (16–25) 63/251 25 (20–31) 7/24 29 (11–47) 191/880 22 (19–24)
2012 34/290 12 (8–15) 35/289 12 (8–16) 25/216 12 (7–16) 6/25 24 (7–41) 100/820 12 (10–14)
2013 3/195 2 (-0.2–3) 7/163 4 (1–7) 2/140 1 (-0.5–3) 0/17 0 (0–0) 12/515 2 (1–4)
2014 2/271 1 (-0.3–2) 0/179 0 (0–0) 0/81 0 (0–0) 0/0 0 (0–0) 2/531 0.4 (−0.1–1)
2015 18/107 17 (10–24) 11′/79 14 (6–22) 3/52 8 (1–15) 0/4 0 (0–0) 33/242 14 (9–18)
2016 56/224 25 (19–31) 51/138 37 (29–45) 12/81 15 (7–23) 1/2 50 (−19–119) 120/445 27 (23–31)
2017 13/61 21 (11–32) 9′/31 29 (13–45) 8′/34 24 (9–38) 0/3 0 (0–0) 30/129 23 (16–31)
2018 41/544 8 (5–10) 40/402 10 (7–13) 22/240 9 (6–13) 1′/20 5 (−5–15) 104/1206 9 (7–10)
Total 1765/7256 24 (23–25) 976/4819 20 (19–21) 324/2102 15 (14–17) 37/173 21 (15–28) 3102/14350 22 (21–22)
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